These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405 [TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049 [TBL] [Abstract][Full Text] [Related]
5. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992 [TBL] [Abstract][Full Text] [Related]
7. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Hernanz A; De la Fuente M; Navarro M; Frank A Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509 [TBL] [Abstract][Full Text] [Related]
8. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949 [TBL] [Abstract][Full Text] [Related]
9. Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1. Lahrtz F; Piali L; Nadal D; Pfister HW; Spanaus KS; Baggiolini M; Fontana A Eur J Immunol; 1997 Oct; 27(10):2484-9. PubMed ID: 9368600 [TBL] [Abstract][Full Text] [Related]
10. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Apostolova LG; Dutton RA; Dinov ID; Hayashi KM; Toga AW; Cummings JL; Thompson PM Arch Neurol; 2006 May; 63(5):693-9. PubMed ID: 16682538 [TBL] [Abstract][Full Text] [Related]
11. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378 [TBL] [Abstract][Full Text] [Related]
13. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077 [TBL] [Abstract][Full Text] [Related]
14. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035 [TBL] [Abstract][Full Text] [Related]
15. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753 [TBL] [Abstract][Full Text] [Related]